An Open Label, Double-Blind Discontinuation Study of Quetiapine XR in Social Anxiety Disorder
| Status: | Completed |
|---|---|
| Conditions: | Anxiety, Healthy Studies, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | January 2008 |
| End Date: | December 2011 |
Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of
quetiapine XR for the treatment of social anxiety disorder (SAD); and 2) continuation
effects of quetiapine XR in preventing SAD relapse.
Inclusion Criteria:
- Adults 18-65 years of age
- A primary diagnosis of SAD, using DSM-IV criteria
- Minimum CGI severity score of 4 and minimum Brief Social Phobia Scale (BSPS) score of
20 at baseline
- Written informed consent
- A negative serum pregnancy test for women of childbearing potential.
Exclusion Criteria:
- Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic
disorder, mental retardation or other pervasive developmental disorder, or cognitive
disorder due to a general medical condition
- Any current primary anxiety disorder other than SAD or current primary depression
- History of substance abuse or dependence within the last 6 months
- Suicide risk or serious suicide attempt within the last year
- Clinically significant medical condition or laboratory abnormality
- Women of childbearing potential who are unwilling to practice an acceptable method of
contraception
- Subjects needing concurrent use of psychotropic medications
- History of hypersensitivity to quetiapine
- History of cataracts.
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
